vs
Side-by-side financial comparison of Home Federal Bancorp, Inc. of Louisiana (HFBL) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.0M, roughly 1.5× Home Federal Bancorp, Inc. of Louisiana). Home Federal Bancorp, Inc. of Louisiana runs the higher net margin — 27.8% vs -60.3%, a 88.2% gap on every dollar of revenue. On growth, Home Federal Bancorp, Inc. of Louisiana posted the faster year-over-year revenue change (18.2% vs -49.9%). Over the past eight quarters, Home Federal Bancorp, Inc. of Louisiana's revenue compounded faster (10.7% CAGR vs -6.7%).
Home Federal Bancorp, Inc. of Louisiana is a U.S. bank holding company based in Louisiana. It operates community banking services via its subsidiary, offering retail customers and local small businesses a full suite of financial products including deposit accounts, consumer loans, mortgage loans, and commercial financing, primarily serving local markets across Louisiana.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
HFBL vs PLX — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.0M | $9.1M |
| Net Profit | $1.7M | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | 35.1% | -51.1% |
| Net Margin | 27.8% | -60.3% |
| Revenue YoY | 18.2% | -49.9% |
| Net Profit YoY | 64.2% | -184.8% |
| EPS (diluted) | $0.54 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.0M | $9.1M | ||
| Q3 25 | $5.9M | $17.9M | ||
| Q2 25 | $5.6M | $15.7M | ||
| Q1 25 | $5.2M | $10.1M | ||
| Q4 24 | $5.1M | $18.2M | ||
| Q3 24 | $4.7M | $18.0M | ||
| Q2 24 | $4.9M | $13.5M | ||
| Q1 24 | $4.9M | — |
| Q4 25 | $1.7M | $-5.5M | ||
| Q3 25 | $1.6M | $2.4M | ||
| Q2 25 | $1.2M | $164.0K | ||
| Q1 25 | $748.0K | $-3.6M | ||
| Q4 24 | $1.0M | $6.5M | ||
| Q3 24 | $941.0K | $3.2M | ||
| Q2 24 | $638.0K | $-2.2M | ||
| Q1 24 | $732.0K | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | 35.1% | -51.1% | ||
| Q3 25 | 34.1% | 11.9% | ||
| Q2 25 | 27.5% | 7.5% | ||
| Q1 25 | 18.3% | -41.0% | ||
| Q4 24 | 23.7% | 39.6% | ||
| Q3 24 | 19.9% | 22.2% | ||
| Q2 24 | 16.9% | -18.0% | ||
| Q1 24 | 18.5% | — |
| Q4 25 | 27.8% | -60.3% | ||
| Q3 25 | 27.1% | 13.2% | ||
| Q2 25 | 20.9% | 1.0% | ||
| Q1 25 | 14.4% | -35.8% | ||
| Q4 24 | 20.0% | 35.6% | ||
| Q3 24 | 19.9% | 18.0% | ||
| Q2 24 | 13.1% | -16.4% | ||
| Q1 24 | 14.9% | — |
| Q4 25 | $0.54 | $-0.06 | ||
| Q3 25 | $0.52 | $0.03 | ||
| Q2 25 | $0.38 | $0.00 | ||
| Q1 25 | $0.24 | $-0.05 | ||
| Q4 24 | $0.33 | $0.10 | ||
| Q3 24 | $0.31 | $0.03 | ||
| Q2 24 | $0.21 | $-0.03 | ||
| Q1 24 | $0.24 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $14.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $57.7M | $48.2M |
| Total Assets | $621.4M | $82.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $14.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $17.9M | ||
| Q1 25 | — | $19.5M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | — | $27.4M | ||
| Q2 24 | — | $23.4M | ||
| Q1 24 | — | — |
| Q4 25 | $57.7M | $48.2M | ||
| Q3 25 | $56.6M | $52.9M | ||
| Q2 25 | $55.2M | $49.9M | ||
| Q1 25 | $54.7M | $45.2M | ||
| Q4 24 | $53.9M | $43.2M | ||
| Q3 24 | $54.3M | $32.4M | ||
| Q2 24 | $52.8M | $28.6M | ||
| Q1 24 | $52.5M | — |
| Q4 25 | $621.4M | $82.3M | ||
| Q3 25 | $622.6M | $82.3M | ||
| Q2 25 | $609.5M | $78.5M | ||
| Q1 25 | $619.6M | $73.9M | ||
| Q4 24 | $607.8M | $73.4M | ||
| Q3 24 | $628.4M | $61.6M | ||
| Q2 24 | $637.5M | $91.5M | ||
| Q1 24 | $643.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.9M | $2.0M |
| Free Cash FlowOCF − Capex | — | $1.6M |
| FCF MarginFCF / Revenue | — | 17.8% |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | 1.70× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.9M | $2.0M | ||
| Q3 25 | $2.8M | $-3.7M | ||
| Q2 25 | $5.5M | $-5.2M | ||
| Q1 25 | $991.0K | $-5.1M | ||
| Q4 24 | $2.6M | $4.0M | ||
| Q3 24 | $871.0K | $4.1M | ||
| Q2 24 | $2.3M | $-3.6M | ||
| Q1 24 | $650.0K | — |
| Q4 25 | — | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | — | $-5.4M | ||
| Q4 24 | — | $3.6M | ||
| Q3 24 | $843.0K | $4.0M | ||
| Q2 24 | $2.3M | $-3.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | — | -53.0% | ||
| Q4 24 | — | 19.6% | ||
| Q3 24 | 17.8% | 22.4% | ||
| Q2 24 | 46.8% | -28.1% | ||
| Q1 24 | — | — |
| Q4 25 | — | 4.4% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 2.8% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.8% | 1.3% | ||
| Q1 24 | — | — |
| Q4 25 | 1.70× | — | ||
| Q3 25 | 1.74× | -1.58× | ||
| Q2 25 | 4.64× | -31.91× | ||
| Q1 25 | 1.32× | — | ||
| Q4 24 | 2.54× | 0.61× | ||
| Q3 24 | 0.93× | 1.27× | ||
| Q2 24 | 3.63× | — | ||
| Q1 24 | 0.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HFBL
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
